162 related articles for article (PubMed ID: 8376592)
21. 11-Dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation.
Catella F; Healy D; Lawson JA; FitzGerald GA
Proc Natl Acad Sci U S A; 1986 Aug; 83(16):5861-5. PubMed ID: 3461463
[TBL] [Abstract][Full Text] [Related]
22. Increased thromboxane biosynthesis in patients with polycythemia vera: evidence for aspirin-suppressible platelet activation in vivo.
Landolfi R; Ciabattoni G; Patrignani P; Castellana MA; Pogliani E; Bizzi B; Patrono C
Blood; 1992 Oct; 80(8):1965-71. PubMed ID: 1327286
[TBL] [Abstract][Full Text] [Related]
23. Increased thromboxane biosynthesis in type IIa hypercholesterolemia.
Davì G; Averna M; Catalano I; Barbagallo C; Ganci A; Notarbartolo A; Ciabattoni G; Patrono C
Circulation; 1992 May; 85(5):1792-8. PubMed ID: 1572035
[TBL] [Abstract][Full Text] [Related]
24. Increased thromboxane B2 excretion in diabetes mellitus.
Katayama S; Inaba M; Maruno Y; Omoto A; Kawazu S; Ishii J
J Lab Clin Med; 1987 Jun; 109(6):711-7. PubMed ID: 3585144
[TBL] [Abstract][Full Text] [Related]
25. Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus.
Santilli F; Davì G; Consoli A; Cipollone F; Mezzetti A; Falco A; Taraborelli T; Devangelio E; Ciabattoni G; Basili S; Patrono C
J Am Coll Cardiol; 2006 Jan; 47(2):391-7. PubMed ID: 16412866
[TBL] [Abstract][Full Text] [Related]
26. Human pharmacology of naproxen sodium.
Capone ML; Tacconelli S; Sciulli MG; Anzellotti P; Di Francesco L; Merciaro G; Di Gregorio P; Patrignani P
J Pharmacol Exp Ther; 2007 Aug; 322(2):453-60. PubMed ID: 17473175
[TBL] [Abstract][Full Text] [Related]
27. Platelet survival and morphology in homocystinuria due to cystathionine synthase deficiency.
Uhlemann ER; TenPas JH; Lucky AW; Schulman JD; Mudd SH; Shulman NR
N Engl J Med; 1976 Dec; 295(23):1283-6. PubMed ID: 980060
[TBL] [Abstract][Full Text] [Related]
28. [Thrombocyte function of healthy probands taking 50 mg of acetylsalicylic acid per day].
Sinzinger H; Kritz H; Pirich C; Karanikas G; Kurtaran A; Banyai M; Peskar BA; Rehak P
Wien Klin Wochenschr; 1995; 107(15):457-63. PubMed ID: 7676685
[TBL] [Abstract][Full Text] [Related]
29. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance.
Frelinger AL; Furman MI; Linden MD; Li Y; Fox ML; Barnard MR; Michelson AD
Circulation; 2006 Jun; 113(25):2888-96. PubMed ID: 16785341
[TBL] [Abstract][Full Text] [Related]
30. Effect of anticardiolipin/beta2-glycoprotein I complexes on production of thromboxane A2 by platelets from patients with the antiphospholipid syndrome.
Robbins DL; Leung S; Miller-Blair DJ; Ziboh V
J Rheumatol; 1998 Jan; 25(1):51-6. PubMed ID: 9458202
[TBL] [Abstract][Full Text] [Related]
31. Thromboxane biosynthesis, neutrophil and coagulative activation in type IIa hypercholesterolemia.
Davì G; Ganci A; Averna M; Giammarresi C; Barbagallo C; Catalano I; Calà A; Notarbartolo A
Thromb Haemost; 1995 Oct; 74(4):1015-9. PubMed ID: 8560403
[TBL] [Abstract][Full Text] [Related]
32. De novo synthesis of cyclooxygenase-1 counteracts the suppression of platelet thromboxane biosynthesis by aspirin.
Evangelista V; Manarini S; Di Santo A; Capone ML; Ricciotti E; Di Francesco L; Tacconelli S; Sacchetti A; D'Angelo S; Scilimati A; Sciulli MG; Patrignani P
Circ Res; 2006 Mar; 98(5):593-5. PubMed ID: 16484611
[TBL] [Abstract][Full Text] [Related]
33. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.
Michiels JJ; Berneman Z; Schroyens W; Finazzi G; Budde U; van Vliet HH
Semin Thromb Hemost; 2006 Sep; 32(6):589-604. PubMed ID: 16977569
[TBL] [Abstract][Full Text] [Related]
34. Aspirin sensitivity of platelet aggregation in diabetes mellitus.
Albert SG; Hasnain BI; Ritter DG; Joist JH; Mooradian AD
Diabetes Res Clin Pract; 2005 Nov; 70(2):195-9. PubMed ID: 15894396
[TBL] [Abstract][Full Text] [Related]
35. Cyclooxygenase-1 haplotype C50T/A-842G does not affect platelet response to aspirin.
Pettinella C; Romano M; Stuppia L; Santilli F; Liani R; Davì G
Thromb Haemost; 2009 Apr; 101(4):687-90. PubMed ID: 19350112
[TBL] [Abstract][Full Text] [Related]
36. Is cardiopulmonary bypass a reason for aspirin resistance after coronary artery bypass grafting?
Zimmermann N; Kurt M; Wenk A; Winter J; Gams E; Hohlfeld T
Eur J Cardiothorac Surg; 2005 Apr; 27(4):606-10. PubMed ID: 15784358
[TBL] [Abstract][Full Text] [Related]
37. Thromboxane generation in patients with essential hypertension or cerebrovascular disease and effect of oral aspirin.
Matsumoto M; Nukada T; Uyama O; Yoneda S; Imaizumi M; Miyamoto T; Kayama N
Thromb Haemost; 1980 Aug; 44(1):16-22. PubMed ID: 7423441
[TBL] [Abstract][Full Text] [Related]
38. Effects of two different HMG-CoA reductase inhibitors on thromboxane production in type IIA hypercholesterolemia.
Milani M; Cimminiello C; Lorena M; Arpaia G; Soncini M; Bonfardeci G
Biomed Pharmacother; 1996; 50(6-7):269-74. PubMed ID: 8952866
[TBL] [Abstract][Full Text] [Related]
39. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance".
Santilli F; Rocca B; De Cristofaro R; Lattanzio S; Pietrangelo L; Habib A; Pettinella C; Recchiuti A; Ferrante E; Ciabattoni G; Davì G; Patrono C
J Am Coll Cardiol; 2009 Feb; 53(8):667-77. PubMed ID: 19232899
[TBL] [Abstract][Full Text] [Related]
40. Platelet activation in patients with colorectal cancer.
Sciulli MG; Filabozzi P; Tacconelli S; Padovano R; Ricciotti E; Capone ML; Grana M; Carnevale V; Patrignani P
Prostaglandins Leukot Essent Fatty Acids; 2005 Feb; 72(2):79-83. PubMed ID: 15626589
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
